Using HIV clinics in Uganda to prevent and detect liver cancer
Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study
['FUNDING_U01'] · JOHNS HOPKINS UNIVERSITY · NIH-11385065
This project brings hepatitis B screening, birth-dose vaccination, and liver cancer checks into HIV care clinics in Uganda to help people with or at risk for HBV and HIV get earlier care.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11385065 on ClinicalTrials.gov |
What this research studies
If you get HIV care at a participating clinic in Uganda, the team will add Hepatitis B screening, newborn birth-dose vaccination and routine liver health checks to your visits. They will adapt the LC3 care package to fit local hospitals and train clinic staff to deliver these services in both cities and rural areas. The project will follow patients' medical records and collect patient feedback to improve how screening and treatment are offered. Over time they will track whether these changes lead to earlier detection and better treatment of liver disease.
Who could benefit from this research
Good fit: Adults receiving HIV care at participating Ugandan clinics, and pregnant people attending antenatal care at those sites, are the main candidates for these services.
Not a fit: People who do not attend participating HIV clinics in Uganda or those whose liver cancer is already too advanced for available treatments may not benefit from this program.
Why it matters
Potential benefit: If successful, this could lead to earlier detection and treatment of liver disease and fewer deaths from liver cancer among people with HBV and HIV in Uganda.
How similar studies have performed: Earlier demonstration projects in Uganda have already integrated HBV services into HIV clinics and launched antenatal screening and birth-dose delivery, showing promising results that this work builds upon.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIRK, GREGORY D — JOHNS HOPKINS UNIVERSITY
- Study coordinator: KIRK, GREGORY D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus